Cargando…
Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect
Intraocular metastasis of cutaneous melanoma is extremely infrequent. This typically occurs in advanced metastatic disease and has a poor survival prognosis. The most frequent reported treatment is radiotherapy. BRAF inhibitors are new, orally administered and very effective drugs used for metastati...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526823/ https://www.ncbi.nlm.nih.gov/pubmed/28744830 http://dx.doi.org/10.1186/s12348-017-0135-2 |
_version_ | 1783252853051097088 |
---|---|
author | Fonollosa, Alex Vargas-Kelsh, Jose Gabriel Garay-Aramburu, Gonzaga Saiz, Angel Zabalza-Estevez, Ignacio Fernandez, Ricardo |
author_facet | Fonollosa, Alex Vargas-Kelsh, Jose Gabriel Garay-Aramburu, Gonzaga Saiz, Angel Zabalza-Estevez, Ignacio Fernandez, Ricardo |
author_sort | Fonollosa, Alex |
collection | PubMed |
description | Intraocular metastasis of cutaneous melanoma is extremely infrequent. This typically occurs in advanced metastatic disease and has a poor survival prognosis. The most frequent reported treatment is radiotherapy. BRAF inhibitors are new, orally administered and very effective drugs used for metastatic cutaneous melanoma. Herein, we report a case of a 58-year-old patient with a recent diagnosis of cutaneous melanoma who consulted for floaters and presented vitreous opacities in both eyes. A diagnostic vitrectomy of his left eye was performed and pathologic analysis disclosed infiltrating melanoma cells in the vitreous. Treatment with dabrafenib (a type of BRAF inhibitor) achieved the regression of the intraocular metastasis in the right eye. Moreover, the patient presented a severe anterior uveitis due to dabrafenib, a well-known secondary effect of this drug. |
format | Online Article Text |
id | pubmed-5526823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-55268232017-08-10 Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect Fonollosa, Alex Vargas-Kelsh, Jose Gabriel Garay-Aramburu, Gonzaga Saiz, Angel Zabalza-Estevez, Ignacio Fernandez, Ricardo J Ophthalmic Inflamm Infect Letter to the Editor Intraocular metastasis of cutaneous melanoma is extremely infrequent. This typically occurs in advanced metastatic disease and has a poor survival prognosis. The most frequent reported treatment is radiotherapy. BRAF inhibitors are new, orally administered and very effective drugs used for metastatic cutaneous melanoma. Herein, we report a case of a 58-year-old patient with a recent diagnosis of cutaneous melanoma who consulted for floaters and presented vitreous opacities in both eyes. A diagnostic vitrectomy of his left eye was performed and pathologic analysis disclosed infiltrating melanoma cells in the vitreous. Treatment with dabrafenib (a type of BRAF inhibitor) achieved the regression of the intraocular metastasis in the right eye. Moreover, the patient presented a severe anterior uveitis due to dabrafenib, a well-known secondary effect of this drug. Springer Berlin Heidelberg 2017-07-25 /pmc/articles/PMC5526823/ /pubmed/28744830 http://dx.doi.org/10.1186/s12348-017-0135-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Letter to the Editor Fonollosa, Alex Vargas-Kelsh, Jose Gabriel Garay-Aramburu, Gonzaga Saiz, Angel Zabalza-Estevez, Ignacio Fernandez, Ricardo Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect |
title | Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect |
title_full | Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect |
title_fullStr | Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect |
title_full_unstemmed | Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect |
title_short | Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect |
title_sort | dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526823/ https://www.ncbi.nlm.nih.gov/pubmed/28744830 http://dx.doi.org/10.1186/s12348-017-0135-2 |
work_keys_str_mv | AT fonollosaalex dabrafenibforcutaneousmelanomainfiltratingthevitreousregressionofmetastasisandoccurrenceofuveitisasasecondaryeffect AT vargaskelshjosegabriel dabrafenibforcutaneousmelanomainfiltratingthevitreousregressionofmetastasisandoccurrenceofuveitisasasecondaryeffect AT garayaramburugonzaga dabrafenibforcutaneousmelanomainfiltratingthevitreousregressionofmetastasisandoccurrenceofuveitisasasecondaryeffect AT saizangel dabrafenibforcutaneousmelanomainfiltratingthevitreousregressionofmetastasisandoccurrenceofuveitisasasecondaryeffect AT zabalzaestevezignacio dabrafenibforcutaneousmelanomainfiltratingthevitreousregressionofmetastasisandoccurrenceofuveitisasasecondaryeffect AT fernandezricardo dabrafenibforcutaneousmelanomainfiltratingthevitreousregressionofmetastasisandoccurrenceofuveitisasasecondaryeffect |